Джейн Плант - Антирак груди

408

Willett, W.C, and Stampfer, M.J., 2007. Rebuilding the food pyramid. Scientific American, Special edition on diet and health, February 2007, 12–21.

409

The Royal Society, 2000. Endocrine-disrupting chemicals. Document 06/00. The Royal Society.

410

Butler, J., 2006. White lies. Vegetarian and Vegan Foundation.

411

Qin, L.Q. and others, 2004. Estrogen: one of the risk factors in milk for prostate cancer. Medical Hypotheses, 62 (1), 133–142.

412

Hartman, S. and others, 1998. Natural occurrence of steroid hormones in food. Food Chemistry, 62, 7-20.

413

Buder, J., 2006. White lies. Vegetarian and Vegan Foundation.

414

Ganmaa, D. and Sato, A., 2005. Possible role of female sex hormones in milk from pregnant cows in the development of breast, ovarian and corpus uteri cancers. Medical Hypotheses, 65 (6), 1028–1037.

415

DEFRA, 2005. Agriculture in the UK, 2004. Norwich, UK: HMSO.

416

Campbell, T.C. and Junshi, C., 1994. Diet and chronic degenerative disease perspectives from China. Am. J. Clin. Nutr., 59, Suppl., 11 535-11 615.

417

Charatan, Fred, 2003. Book Review: Fat Land: How Americans Became the Fattest People in the World, by Greg Critser. BMJ, 326, 229.

418

Charatan, Fred, 2003. Book Review: Fat Land: How Americans Became the Fattest People in the World, by Greg Critser. BMJ, 326, 229.

419

Charatan, Fred, 2003. Book Review; Fat Land; How Americans Became the Fattest People in the World, by Greg Critser. BMJ, 326, 229.

420

Grosvenor, C.E. and others, 1992. Hormones and growth factors in milk. Endocrine Reviews, 14 (6), 710–728.

421

http://www.dhn.csiro.au/crctissue.html

422

http://www.13.waisays.com/cancer2.htm

423

le Huerou-Luron, I. and others, 1998. Source of dietary protein influences kinetics of plasma gut regulatory peptide concentration to feeding in preruminant calves. Comparative Biochemistry and Physiology: A – Molecular and Integrative Physiology, 119 (3), 817–824.

424

Koldovski, O. and others, 1995. Milk-borne hormones: possible tools of communication between mother and suckling. Physiological Research, 1995, 44 (6), 349–351, Koldovsky, O. and others, 1994. Hormonally active peptides in human milk. Acta Paediatrica Suppl., 402, 89–93; Lehy,T. and others, 1990. Promoting effect of bombesin on the cell proliferation in the rat endocrine pancreas during the early post natal period. Regulatory Peptides, 27 (1), 87–96; Pollack, P.F., 1989. Effects of enterally– and parenterally-administrated bombesin on intestinal luminaltryptic activity and protein in the suckling rat. Experienta, 45 (4), 385–388; Lazarus, L.H. and others, 1986. An immunoreactive peptide in milk contains bombesin-like bioactivity. Experienta, 42 (7), 822–823; Jahnke, G.D. and others, 1984. A bombesin immunoreactive peptide in milk. Proc. Natl. Acad. Sci. USA, 81 (2), 578–582.

425

Berseth, C.I. and others, 1990. Postpartum changes in pattern of gastrointestinal regulatory peptides in human milk. Am. J. Clin. Nutr., 51 (6), 985–990.

426

Burns, D.M. and others, 1999. Breast cancer cell-associated endopeptidase EC24.11 modulates proliferative response to bombesin, British Journal of Cancer, 79 (2), 214–220; Bold, R.J, and others, 1998. Bombesin stimulates in vitro growth of human breast cancer independent of estrogen receptor status. Anticancer Research, 18 (16A), 4051–4056; Miyazaki, M. and others, 1998. Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-11 and RC-3095. European Journal of Cancer, 34 (5), 710–717; Nelson, J, and others, 1991. Bombesin stimulates proliferation of human breast cancer cells in culture. Br. J. Cancer, 63 (6), 933–936; Giacchetti, S. and others, 1990. Characterization, in some human breast cancer cell lines, of gastrin-releasing peptide-like receptors which are absent in normal breast epithelial cells. Int J. Cancer, 46 (2), 293–298; Weber, C.J. and others, 1989. Gastrin-releasing peptide, calcitonin gene-related peptide, and calcitonin-like immuno-reactivity in human breast cystfluid and gastrin-releasing peptide-like immunoreactivity in human breast carcinoma cell lines. Surgery, (6), 1134–1139 (disc. 1139–1140).

427

Markwalder, R. and others, 1999. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Research, 59 (5), 1152–1159; Festuccia, C. and others, 1998. In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin. Int. J. Cancer, 75 (3); 418–431: Krongrad, A. and others, 1997. Endopeptidase 24.11 activity in the human prostate cancer cell lines LNCaP and PPC-1. Urological Research, 25 (2), 113–116; Jungwirth, A. and others, 1997. LHRH antagonist Cetrolix (SB-75) and bombesin-antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Prostate, 32 (3), 164–172; Larran, J. and others, 1996. In vitro characterization of bombesin and calcitonin on the proliferation of PC3, DK145 and LNCaP cancer prostatic cell lines. International Journal of Developmental Biology, 1996 (Suppl. 1), 275S–276S; Aprickian, A.G. and others, 1996. Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostatic cancer cells. Journal of Molecular Endocrinology, 16 (3), 297–306; Bologna, M. and others, 1989. Bombesin stimulates growth of human prostatic cancer cells in vitro. Cancer, 63 (9), 1714–1720; Wasilenko, W.J. and others, 1996. Effects of the calcium influx inhibitor carboxyamido-triazole on the proliferation and invasiveness of human prostate tumor cell lines. Int J. Cancer, 68 (2), 259–264.

428

Takeyama, M. and others, 1989. Enzyme immunoassae of gastrin-releasing, peptide (GRP)-like immunoreactivity in milk. Int. J. Pept. Protein Res., 34 (1), 70–74.

429

Ducroc, R. and others, 1995. Immunoreactive substance P and calcitonin-gene-related peptide (CGRP) in rat milk and in human milk and infant formula's. Am. J. Clin. Nutr., 62 (3), 554–558.

430

Lembeck, F. and others, 1979. Substance P as neurogenic mediator of antidromic vasodilation and neurogenic plasma extravasation. Arch. Pharmacol., 310 (2), 175–183.

431

Khare, V. K. and others, 1998. The neuropeptide/mast cell secretagogue substance F is expressed in cutaneous melanocyticlesions. Journal of Cutaneous Pathology, 25 (1), 2-10.

432

Ducroc, R. and others, 1995. Immunoreactive substance P and calcitonin-gene-related peptide (CGRP) in rat milk and in human milk and infant formula's. Am. J. Clin. Nutr., 62 (3), 554–558.

433

Faulkner, A., 1998. Insulin-like growth factor 1 concentrations in milk and plasma after growth hormone treatment. Biochemical Society Transactions, 26 (4), 386; Silanikove, N. and others, 1998. Metabolic and productive response of dairy cows to increased ion supplementation at early lactation in warm weather. Journal of Dairy Research, 65 (4), 529–543; Ginjala, V. and others, 1998. Determination of transforming growth factor-beta 1 (TGF-beta 1) and insulin-like growth factor-1 (IGF-1) in bovine colostreum samples. Journal of Immunoassay, 19 (2–3), 195–207; Schober, D.A. and others, 1990. Perinatal expression of type 1 IGF receptors in porcine small intestine. Endocrinology, 126 (2), 1125–1132.

434

Rao, R.K. and others, 1998. Luminal stability of insulin-like growth factor-1 and -2 in developing rat gastrointestinal tract. Journal of Pediatric Gastroenterology and Nutrition, 26 (2), 179–185.

435

Parisot, J.P. and others, 1999. Altered expression of the insulinlike growth factor-1 receptor in a tamoxifen-resistant human breast cancer cell line. Br. J. Cancer, 79 (5–6), 693–700; Sciacca, L. and others, 1999. Insulin receptor activation by insulin-like growth factor– 2 in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene, 18 (15), 2471–2479; Grothey, A. and others, 1999. The role of insuline-like growth factor and its receptor in cell growth transformation, apoptosis, and chemoresistance In solid tumors. Journal of Cancer Research and Clinical Oncology, 125 (3–4), 166–173; Perks, C. M. and others, 1999. Activation of integrin and ceramide signalling pathways can inhibit the mitogenic effect of insulin-like growth factor-1 (IGF-1) in human breast cancer cell lines. Br. J. Cancer, 79 (5–6), 701–706; de Cupis, A. and others, 1998. Responsiveness to hormone, growth factor and drug treatment of a human breast cancer cell line; comparison between early and late cultures. In Vitro Cellular and Developmental Biology – Animal, 34 (10), 836–843; Kobari, M. and others, 1998. The inhibitory effect of an epidermal growth factor receptor specific tyrokinase inhibitor on pancreatic cancer cell lines was more potent than inhibitory antibodies against the receptors for EGF and IGF-1. International Journal of Pancreatology, 24 (2), 85–95; Gooch, J.L. and others, 1998. Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. Cancer Res., 58 (18), 4199–4205; Choki, I. and others, 1998. Osteobiast-derived growth factors enhance adriamycin-cytostasis of MCF-7 human breast cancer cells. Anticancer Res., 18 (16A), 4213–4224; Jackson, J.G. and others, 1998, Insulin receptor substrate-1 is the predominant signalling molecule activated by insulin-like growth factor-1, insulin, and interleukin– 4 in estrogen receptor-positive human breast cancer cells. Journal of Biological Chemistry, 273 (16), 9994-10 003; Westley, B.R. and others, 1998. Interactions between the oestrogen and IGF signalling pathways in the control of breast epithelial cell proliferation. Biochemical Society Symposium, 63, 35–44; Surmacz, E. and others, 1995. Overexpression of insulin receptor substrate 1 (IRS-1) in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation. Clinical Cancer Research, 1 (11), 1429–1436.